Investigational drug · Phase 3
Zeleciment Rostudirsen
Also called: DYNE-251
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD).
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "Zeleciment Rostudirsen"
First trial start
2022
Aug 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zeleciment Rostudirsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Duchenne Muscular Dystrophy (DMD)
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy (DMD)
- DMD
- Muscular Dystrophies
- Muscular Dystrophy in Children
- Muscular Dystrophy, Duchenne Type
- Muscular Dystrophy, Duchenne and Becker Types
- Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
- Genetic Disease, Inborn
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Zeleciment Rostudirsen" as an intervention, largest first.
- Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)Pivotal-lookingRecruiting
Dyne TherapeuticsIndustry
NCT07608432 · 90 participants (planned) · Start Jun 2026 · Primary completion Dec 2030
Drug: Zeleciment Rostudirsen (DYNE-251); Placebo · For: Duchenne Muscular Dystrophy (DMD); Muscular Dystrophy, Duchenne; Muscular Dystrophy (DMD) and 10 more
Sites: Hillsborough, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Duchenne Muscular Dystrophy (DMD)
- BrogidirsenNS-089, NCNP-02Phase 23 trials
NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD
- BMN 351Phase 22 trials
BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy
- ENTR-601-44Phase 22 trials
Entrada Therapeutics, Inc. · Duchenne Muscular Dystrophy (DMD)
- ENTR-601-45Phase 22 trials
Entrada Therapeutics, Inc. · Duchenne Muscular Dystrophy (DMD)
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.